BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 34159865)

  • 1. Prognostic Value of Immune-Related lncRNA SBF2-AS1 in Diffuse Lower-Grade Glioma.
    Zhang Q; Liu XJ; Li Y; Ying XW; Chen L
    Technol Cancer Res Treat; 2021; 20():15330338211011966. PubMed ID: 34159865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
    Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
    Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma.
    Zhang JH; Hou R; Pan Y; Gao Y; Yang Y; Tian W; Zhu YB
    J Cell Mol Med; 2020 Jul; 24(13):7504-7514. PubMed ID: 32412186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Clinical Prognostic Value of lncRNA SBF2-AS1 in Cancer Patients: A Meta-Analysis.
    Wang J; Zhong P; Hua H
    Technol Cancer Res Treat; 2021; 20():15330338211004915. PubMed ID: 33906548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
    Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
    Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic screening identifies GABRD, a subunit gene of GABAA receptor as a prognostic marker in adult IDH wild-type diffuse low-grade glioma.
    Zhang H; Zhang L; Tang Y; Wang C; Chen Y; Shu J; Zhang K
    Biomed Pharmacother; 2019 Oct; 118():109215. PubMed ID: 31545245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and Prognostic Potentials of Long Noncoding RNA ELF3-AS1 in Glioma Patients.
    Mei JC; Yan G; Mei SQ
    Dis Markers; 2020; 2020():8871746. PubMed ID: 33014189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An autophagic gene-based signature to predict the survival of patients with low-grade gliomas.
    Chen J; Li Y; Han X; Pan Y; Qian X
    Cancer Med; 2021 Mar; 10(5):1848-1859. PubMed ID: 33591634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phospholipase Cγ1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients.
    Li T; Yang Z; Li H; Zhu J; Wang Y; Tang Q; Shi Z
    Lab Invest; 2022 Feb; 102(2):143-153. PubMed ID: 34697421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
    Xu S; Tang L; Liu Z; Luo C; Cheng Q
    Front Immunol; 2021; 12():731048. PubMed ID: 34659218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Long Noncoding RNA ZNF667-AS1 as a Potential Biomarker for Diagnosis and Prognosis of Glioma Patients.
    Yuan Q; Gao C; Lai XD; Chen LY; Lai TB
    Dis Markers; 2020; 2020():8895968. PubMed ID: 33282010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RUNX1 and REXO2 are associated with the heterogeneity and prognosis of IDH wild type lower grade glioma.
    Wang H; Wang X; Xu L; Zhang J; Cao H
    Sci Rep; 2021 Jun; 11(1):11836. PubMed ID: 34088969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma.
    Mou Y; Zhang L; Liu Z; Song X
    BMC Cancer; 2022 Feb; 22(1):215. PubMed ID: 35227235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Up‑regulation of lncRNA PXN-AS1-L is associated with unfavorable prognosis in patients suffering from glioma.
    Shang F; Du SW; Ma XL
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8950-8955. PubMed ID: 31696482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
    Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
    Front Immunol; 2020; 11():603341. PubMed ID: 33363544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
    Hao YP; Wang WY; Qiao Q; Li G
    Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Over-expression of lncRNA SBF2-AS1 is associated with advanced tumor progression and poor prognosis in patients with non-small cell lung cancer.
    Zhao QS; Li L; Zhang L; Meng XW; Li LL; Ge XF; Li ZP
    Eur Rev Med Pharmacol Sci; 2016 Jul; 20(14):3031-4. PubMed ID: 27460731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.